Medicare’s drug pricing negotiations — the first of their kind in the United States, passed under President Joe Biden — face an uncertain future in the incoming Trump administration.

Given that more than 40% of Indian adults are struggling with obesity and diabetes, affordable weight-loss drugs are expected to significantly disrupt the pharmaceutical landscape in the country this year.

Weight loss drugs have risen in popularity in the recent years, but a disconnect remains between those who need the drugs and those who can afford to buy them. Drugs like Ozempic, which isn’t available in New Zealand,

Dr. Mehmet Furkan Burak said people who have lost weight and then gained it again can feel guilt or shame and blame themselves for it.

As the new year sparks a wave of weight loss resolutions and millions turn to weight loss medications, rising costs and the growing popularity of compounded alternatives have raised critical questions.

Over her three-decade career, weight management physician Dr. Sarah Ro has seen hundreds of patients. Many of them are on Medicaid and have become yo-yo dieters who, despite their best efforts at changing their eating habits and lifestyles,

McGill University researchers say their study has found GLP-1 drugs are safe and effective for treating obesity and overweight adults without diabetes. The authors say the findings support using the medication to treat those who are overweight and obese among otherwise healthy patients.

The U.S. FDA has released a new draft guidance for drugmakers to aid them in developing new treatments for obesity. The new document replaces an earlier draft guidance issued in February 2007. The new guidance stated that its focus is on the design of clinical trials and endpoints to demonstrate sustained weight loss,